Pandemic-related disruptions led to a 25% drop in the number of people starting treatment for hepatitis C, according to findings presented at the 2021 International Liver Congress virtual meeting. Even prior to the COVID-19 pandemic disrupting HCV testing and treatment services, the United States was not on track to meet WHO targets. Compared with 2019, however, 25% fewer individuals began antiviral therapy for hepatitis C in 2020. While 160,000 to 170,000 individuals were expected to start HCV treatment since 2019, fewer than 150,000 individuals actually began receiving the medications. Click here to learn more about hepatitis C.
At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.